首页|戈舍瑞林联合戊酸雌二醇治疗子宫内膜异位症术后患者的效果

戈舍瑞林联合戊酸雌二醇治疗子宫内膜异位症术后患者的效果

扫码查看
目的:观察戈舍瑞林联合戊酸雌二醇治疗子宫内膜异位症(EMT)术后患者的效果.方法:选取 2021 年 4 月至 2022 年4 月该院收治的 60 例EMT术后患者进行前瞻性研究,按照随机数字表法将其分为对照组和研究组各 30 例.对照组采用戊酸雌二醇治疗,研究组在对照组基础上联合戈舍瑞林治疗.比较两组临床疗效,治疗前后痛经程度[视觉模拟评分法(VAS)]评分、月经量[月经失血图(PBAC)]评分、性激素[黄体生成素(LH)、卵泡刺激素(FSH)、雌二醇(E2)]水平、血清学指标[血管内皮生长因子(VEGF)、可溶性细胞间黏附分子-1(sICAM-1)]水平,不良反应发生率及 1 年复发率.结果:研究组治疗总有效率为 93.33%(28/30),高于对照组的 73.33%(22/30),差异有统计学意义(P<0.05);治疗后,两组VAS、PBAC评分均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组LH、FSH、E2 水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组VEGF、sICAM-1水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05);随访1年,研究组失访2例,对照组失访5例,研究组复发率为3.57%(1/28),低于对照组的32.00%(8/25),差异有统计学意义(P<0.05).结论:戈舍瑞林联合戊酸雌二醇治疗EMT术后患者,可提高临床疗效,减轻痛经程度,减少月经失血量,改善性激素水平,降低VEGF、sICAM-1 水平和复发率,效果优于单纯戊酸雌二醇治疗.
Effects of Goserelin combined with Estradiol valerate in treatment of postoperative patients with endometriosis
Objective:To observe effect of Goserelin combined with Estradiol valerate in the treatment of postoperative patients with endometriosis(EMT).Methods:A prospective study was conducted on 60 patients with EMT admitted to the hospital from April 2021 to April 2022.According to the random number table method,they were divided into control group and study group,30 cases in each group.The control group was treated with Estradiol valerate,while the study group was treated with Goserelin on the basis of that of the control group.The clinical efficacy,the dysmenorrhea degree[visual analogue scale(VAS)]and menstrual volume[pictorial blood loss assessment chart,(PBAC)]scores,the levels of sex hormone indexes[luteinizing hormone(LH),follicle stimulating hormone(FSH),Estradiol(E2)]and serological indexes[vascular endothelial growth factor(VEGF),soluble intercellular adhesion molecule-1(sICAM-1)],the incidence of adverse reactions,and the 1-year recurrence rate were compared between the two groups before and after the treatment.Results:The total effective rate of the study group was 93.33%(28/30),which was higher than 73.33%(22/30)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the VAS and PBAC scores of the two groups were lower than those before the treatment,those of the study group were lower than those of the control group,and the differences were statistically significant(P<0.05).The levels of LH,FSH and E2 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of VEGF and sICAM-1 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After 1 year of follow-up,2 cases were lost in the study group and 5 cases in the control group.The recurrence rate of the study group was 3.57%(1/28),which was lower than 32.00%(8/25)of the control group,and the difference was statistically significant(P<0.05).Conclusions:Goserelin combined with Estradiol valerate in the treatment of the postoperative patients with EMT can improve the clinical efficacy,reduce the degree of dysmenorrhea and the menstrual blood loss,improve the levels of sex hormones,and reduce the levels of VEGF,sICAM-1 and the recurrence rate.Moreover,it is superior to single Estradiol valerate treatment.

GoserelinEstradiol valerateEndometriosisPainMenstrual volumeSex hormone

尹丽娜

展开 >

夏邑县第二人民医院妇产科,河南 商丘 476400

戈舍瑞林 戊酸雌二醇 子宫内膜异位症 疼痛 月经量 性激素

2024

中国民康医学
中国社会工作协会

中国民康医学

影响因子:0.649
ISSN:1672-0369
年,卷(期):2024.36(11)
  • 14